Published in

Ivyspring International Publisher, Theranostics, 3(6), p. 418-427

DOI: 10.7150/thno.14018

Links

Tools

Export citation

Search in Google Scholar

Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept Before Phase I Trial.

Journal article published in 2016 by Shady Kotb, Alexandre Detappe, Francois Lux, Florence Appaix, Emmanuel L. Barbier ORCID, Vu-Long Tran, Marie Plissonneau, Hélène Géhan, Florence Lefranc, Claire Rodriguez-Lafrasse, Camille Verry, Ross Berbeco, Olivier Tillement, Lucie Sancey
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium (Gd) is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use of imaging to guide the irradiation and to delineate the tumor. In this study, we used the Gd-based nanoparticles, AGuIX®. After intravenous injection into animals bearing B16F10 tumors, some nanoparticles remained inside the tumor cells for more than 24 hours, indicating that a single administration of nanoparticles might be sufficient for several irradiations. Combining AGuIX® with radiation therapy increases tumor cell death, and improves the life spans of animals bearing multiple brain melanoma metastases. These results provide pre-clinical proof-of-concept for a phase I clinical trial.